Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression
November 17, 2021 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Reports Third Quarter 2021 Financial Results
November 10, 2021 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)
November 10, 2021 16:04 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021
October 27, 2021 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market...
Sight Sciences Announces TearCare® Clinical Data Published in Cornea
October 20, 2021 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most...
Sight Sciences Files Lawsuit Against Ivantis for Patent Infringement
September 16, 2021 18:29 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis,...
Sight Sciences to Participate in the Morgan Stanley Global Healthcare Conference
August 26, 2021 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address...
Sight Sciences, Pioneering the Development of the Standalone MIGS Market, Announces Publication of Favorable Two-Year Outcomes of Standalone Use of the OMNI® Surgical System in Mild to Moderate Open-Angle Glaucoma
August 24, 2021 08:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address...
Sight Sciences Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences to Report Second Quarter 2021 Financial Results on August 12, 2021
August 02, 2021 16:34 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on...